<DOC>
	<DOCNO>NCT02854618</DOCNO>
	<brief_summary>This study evaluate immune response patient affect metastatic breast cancer treat everolimus</brief_summary>
	<brief_title>Immune Response Patients With Metastatic Breast Cancer Treated Everolimus</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>patient eligible treatment everolimus association exemestane Performance status 0,1 2 accord WHO Patients affect breast cancer advance and\or metastatic HER2 negative express hormonal receptor RH + menopausal Patients Psychiatric disease compromise understanding information realization study Vulnerable people accord law ( minor , adult protection , private person freedom ) Histories cancer 5 year precede diagnosis ( except breast cancer , squamouscell ) Not menopausal woman Unaffiliated people Social Security People period exclusion another study Hypersensitivity active substance , byproducts rapamycin one excipients . Symptomatic visceral achievement Legal incapacity limit legal capacity</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>